Iodinated contrast (IC) often is overlooked as a cause of delayed drug reactions. As a result, patients may continue to be readministered these agents, experiencing preventable morbidity. We report an illustrative case of a delayed cutaneous reaction to IC and review the literature on the epidemiology and management of this underrecognized phenomenon.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Neutrophilic Panniculitis Secondary to BRAF and MEK Inhibitor Therapy to Treat Stage IIIa Cutaneous Melanoma.
J Cutan Pathol
January 2025
Department of Dermatology, San Antonio Uniformed Services Health Consortium (SAUSHEC), San Antonio, Texas, USA.
Panniculitides are a group of inflammatory disorders of the subcutaneous fat that have been reported as a rare complication of both a serine threonine kinase BRAF inhibitor monotherapy and BRAF inhibition in combination with a mitogen activated protein kinase (MEK) inhibitor combination therapy used to treat metastatic melanoma. The cutaneous manifestations of BRAF and BRAF/MEK therapies have been well documented, but neutrophilic panniculitis remains a less common complication with fewer case reports. Physician awareness of this complication when following patients on similar targeted therapies can decrease delays in appropriate management.
View Article and Find Full Text PDFBacterial isolates and drug susceptibility patterns in infected lesions of cutaneous leishmaniasis patients at ALERT hospital, Addis Ababa, Ethiopia.
BMC Infect Dis
January 2025
Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University, Addis Ababa, P.O. Box 9086, Addis Ababa, Ethiopia.
Bacterial infections commonly complicate cutaneous leishmaniasis (CL), worsening the disease and delaying healing. Despite this, there is a gap in research concerning the characteristics of pathogenic microorganisms associated in CL patients. This study aims to identify bacterial isolates and drug susceptibility patterns in CL patients.
View Article and Find Full Text PDFHistopathological Diagnostic Discordance between Punch Biopsies and Final Diagnostic Excisions of Cutaneous Squamous Cell Carcinoma: Analysis of 737 Cases.
Acta Derm Venereol
January 2025
Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
The recommended treatment for cutaneous squamous cell carcinoma is surgical excision. An initial punch biopsy is often performed as an aid to diagnosis. A retrospective registry-based study was performed to assess histopathological concordance of punch biopsy of cutaneous squamous cell carcinoma and subsequent excision.
View Article and Find Full Text PDFDigital Papillary Adenocarcinoma at the Site of 5 Years of Recurrent Paronychia: Case Report and Literature Review.
Case Rep Oncol Med
December 2024
Hand and Upper Extremity Surgery, Barrington Orthopedic Specialists, Schaumburg, Illinois, USA.
Article Synopsis
- Digital papillary adenocarcinoma (DPA) is a rare and often misdiagnosed malignant tumor, commonly mistaken for benign conditions, leading to delayed diagnosis and treatment.
- A 57-year-old man with recurrent finger infections was ultimately diagnosed with DPA after a surgical evaluation and biopsy revealed both infection and the tumor, necessitating surgical removal.
- Accurate diagnosis is vital due to the tumor's tendency for recurrence and metastasis, particularly to the lungs and lymph nodes, and current treatment primarily involves surgical excision with focus on achieving negative margins.
Tralokinumab Treatment of Atopic Dermatits Induces A Progressive Transcriptomic Response.
J Invest Dermatol
December 2024
Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. Electronic address:
Atopic dermatitis (AD) is characterized by a complex epidermal barrier deficiency and exaggerated immune responses dominated by type-2-mechanisms with variable contributions of additional immune axes. Interleukin (IL)-13 is overexpressed in AD skin and a key driver of both barrier dysfunction and inflammation. We here prospectively studied the effects of IL-13 inhibition with tralokinumab on cutaneous transcriptome profiles using RNA sequencing of biopsies from 16 moderate-to-severe AD patients obtained at baseline, week 2 and week 16.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!